Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112


CSNK1E/CTNNB1 are synthetic lethal to TP53 in colorectal cancer and are markers for prognosis.

Tiong KL, Chang KC, Yeh KT, Liu TY, Wu JH, Hsieh PH, Lin SH, Lai WY, Hsu YC, Chen JY, Chang JG, Shieh GS.

Neoplasia. 2014 May;16(5):441-50. doi: 10.1016/j.neo.2014.04.007. Epub 2014 Jun 17.


Uncovering synthetic lethal interactions for therapeutic targets and predictive markers in lung adenocarcinoma.

Chang JG, Chen CC, Wu YY, Che TF, Huang YS, Yeh KT, Shieh GS, Yang PC.

Oncotarget. 2016 Nov 8;7(45):73664-73680. doi: 10.18632/oncotarget.12046.


Combined Immunohistochemistry of PLK1, p21, and p53 for Predicting TP53 Status: An Independent Prognostic Factor of Breast Cancer.

Watanabe G, Ishida T, Furuta A, Takahashi S, Watanabe M, Nakata H, Kato S, Ishioka C, Ohuchi N.

Am J Surg Pathol. 2015 Aug;39(8):1026-34. doi: 10.1097/PAS.0000000000000386.


Associations of beta-catenin alterations and MSI screening status with expression of key cell cycle regulating proteins and survival from colorectal cancer.

Wangefjord S, Brändstedt J, Lindquist KE, Nodin B, Jirström K, Eberhard J.

Diagn Pathol. 2013 Jan 21;8:10. doi: 10.1186/1746-1596-8-10.


Association between KIAA1199 overexpression and tumor invasion, TNM stage, and poor prognosis in colorectal cancer.

Xu J, Liu Y, Wang X, Huang J, Zhu H, Hu Z, Wang D.

Int J Clin Exp Pathol. 2015 Mar 1;8(3):2909-18. eCollection 2015.


TP53 mutation is frequently associated with CTNNB1 mutation or MYCN amplification and is compatible with long-term survival in medulloblastoma.

Pfaff E, Remke M, Sturm D, Benner A, Witt H, Milde T, von Bueren AO, Wittmann A, Schöttler A, Jorch N, Graf N, Kulozik AE, Witt O, Scheurlen W, von Deimling A, Rutkowski S, Taylor MD, Tabori U, Lichter P, Korshunov A, Pfister SM.

J Clin Oncol. 2010 Dec 10;28(35):5188-96. doi: 10.1200/JCO.2010.31.1670. Epub 2010 Nov 8.


PTGER2 overexpression in colorectal cancer is associated with microsatellite instability, independent of CpG island methylator phenotype.

Baba Y, Nosho K, Shima K, Goessling W, Chan AT, Ng K, Chan JA, Giovannucci EL, Fuchs CS, Ogino S.

Cancer Epidemiol Biomarkers Prev. 2010 Mar;19(3):822-31. doi: 10.1158/1055-9965.EPI-09-1154. Epub 2010 Mar 3.


CYP24A1 is a potential biomarker for the progression and prognosis of human colorectal cancer.

Sun H, Wang C, Hao M, Sun R, Wang Y, Liu T, Cong X, Liu Y.

Hum Pathol. 2016 Apr;50:101-8. doi: 10.1016/j.humpath.2015.11.008. Epub 2015 Nov 28.


Molecular correlates and prognostic significance of SATB1 expression in colorectal cancer.

Nodin B, Johannesson H, Wangefjord S, O'Connor DP, Lindquist KE, Uhlén M, Jirström K, Eberhard J.

Diagn Pathol. 2012 Aug 30;7:115. doi: 10.1186/1746-1596-7-115.


Association of the p53 codon 72 polymorphism with clinicopathological characteristics of colorectal cancer through mRNA analysis.

De Oliveira LP, López I, Dos Santos EM, Tucci P, Marín M, Soares FA, Rossi BM, Coudry Rde A.

Oncol Rep. 2014 Mar;31(3):1396-406. doi: 10.3892/or.2013.2940. Epub 2013 Dec 20.


Comparison of neuroendocrine differentiation and KRAS/NRAS/BRAF/PIK3CA/TP53 mutation status in primary and metastatic colorectal cancer.

Kleist B, Kempa M, Novy M, Oberkanins C, Xu L, Li G, Loland C, Poetsch M.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):5927-39. eCollection 2014.


Effects of altered expression and activity levels of CK1δ and ɛ on tumor growth and survival of colorectal cancer patients.

Richter J, Ullah K, Xu P, Alscher V, Blatz A, Peifer C, Halekotte J, Leban J, Vitt D, Holzmann K, Bakulev V, Pinna LA, Henne-Bruns D, Hillenbrand A, Kornmann M, Leithäuser F, Bischof J, Knippschild U.

Int J Cancer. 2015 Jun 15;136(12):2799-810. doi: 10.1002/ijc.29346. Epub 2014 Dec 1. Erratum in: Int J Cancer. 2016 Aug 15;139(4):E5.


Alpha B-crystallin correlates with poor survival in colorectal cancer.

Shi C, He Z, Hou N, Ni Y, Xiong L, Chen P.

Int J Clin Exp Pathol. 2014 Aug 15;7(9):6056-63. eCollection 2014.


Somatic molecular changes and histo-pathological features of colorectal cancer in Tunisia.

Aissi S, Buisine MP, Zerimech F, Kourda N, Moussa A, Manai M, Porchet N.

World J Gastroenterol. 2013 Aug 28;19(32):5286-94. doi: 10.3748/wjg.v19.i32.5286.


Methylation epigenotypes and genetic features in colorectal laterally spreading tumors.

Sakai E, Ohata K, Chiba H, Matsuhashi N, Doi N, Fukushima J, Endo H, Takahashi H, Tsuji S, Yagi K, Matsusaka K, Aburatani H, Nakajima A, Kaneda A.

Int J Cancer. 2014 Oct 1;135(7):1586-95. doi: 10.1002/ijc.28814. Epub 2014 Mar 10.


High Rab27A expression indicates favorable prognosis in CRC.

Shi C, Yang X, Ni Y, Hou N, Xu L, Zhan F, Zhu H, Xiong L, Chen P.

Diagn Pathol. 2015 Jun 13;10:68. doi: 10.1186/s13000-015-0303-3.


Increased expression of prothymosin-α, independently or combined with TP53, correlates with poor prognosis in colorectal cancer.

Zhang M, Cui F, Lu S, Lu H, Jiang T, Chen J, Zhang X, Jin Y, Peng Z, Tang H.

Int J Clin Exp Pathol. 2014 Jul 15;7(8):4867-76. eCollection 2014.


Increased expression of Rab5A predicts metastasis and poor prognosis in colorectal cancer patients.

Yu MH, Luo Y, Qin SL, Zhong M.

Int J Clin Exp Pathol. 2015 Jun 1;8(6):6974-80. eCollection 2015.


CK1epsilon is required for breast cancers dependent on beta-catenin activity.

Kim SY, Dunn IF, Firestein R, Gupta P, Wardwell L, Repich K, Schinzel AC, Wittner B, Silver SJ, Root DE, Boehm JS, Ramaswamy S, Lander ES, Hahn WC.

PLoS One. 2010 Feb 1;5(2):e8979. doi: 10.1371/journal.pone.0008979.


Positive feedback loop of hepatoma-derived growth factor and β-catenin promotes carcinogenesis of colorectal cancer.

Lian J, Tang J, Shi H, Li H, Zhen T, Xie W, Zhang F, Yang Y, Han A.

Oncotarget. 2015 Oct 6;6(30):29357-74. doi: 10.18632/oncotarget.4982.

Supplemental Content

Support Center